The AI-native books platform backed by KAUST Innovation Ventures, DisrupTech Ventures, and a coalition of leading investors is transforming the way people read, bringing books to life as living, interactive aiBook™ experiences

SUNNYVALE, Calif., April 20, 2026 — Sinai.ai, an AI-native books platform, today announced the close of its $1.45M pre-seed funding round, led by KAUST Innovation Ventures (KIV) and DisrupTech Ventures, with participation from Maza Ventures and YOUXEL Ventures, alongside a coalition of angel investors. The capital will fund proprietary tech, AI infrastructure, user acquisition, and licensing.

The $150 billion global book market has seen little innovation in format for decades. Sinai was built to change that. At the heart of the platform is the aiBook™, a trademarked, patent-backed book format built on 100% licensed, full-text content. Readers can converse with their book in real time, generate study guides and quizzes, access titles across multiple languages, and switch between reading and listening. Sinai is launching with thousands of titles, having already secured partnerships with double-digit publishers, including several prominent names in the industry.

Investor Perspectives

“We strongly believe that AI will fundamentally reshape a wide range of industries, and the book industry is long overdue for meaningful innovation. For over two decades, the core format of books has remained largely unchanged. What the Sinai.ai team is building introduces a truly new paradigm — transforming books into interactive, intelligent experiences where readers can engage, learn, and explore in entirely new ways. We are particularly excited about the team and their ability to execute on a vision that sits at the intersection of content, technology, and user experience. We are always proud to back Egyptian founders who are building category-defining companies and pushing the boundaries of innovation beyond local markets.”
— Mohamed El Sayed Okasha, DisrupTech Ventures

“What drew me to Sinai.ai is that they’re approaching a huge, old industry with respect and clarity. Publishing has been around for centuries, and for good reason, but much of how it operates hasn’t evolved at the pace of technology. Instead of trying to break it, Sinai.ai is working alongside it, using AI to modernize how books are created, produced, and distributed. That’s a harder path. It requires understanding the incentives of everyone involved and building something that fits into a real ecosystem, not just replacing it. But it’s also the more enduring one. The companies that last are often the ones that reshape industries from within, and Sinai.ai feels like it’s doing exactly that.”
— Tambi Jalouqa, Maza Ventures

About the Team

Sinai.ai was co-founded by five individuals: Ahmed Kamel (CEO), a serial tech entrepreneur with post-graduate studies in AI and innovation at Stanford; Mohamed Elshamy (CRO), Yale MBA, with experience at Google, McKinsey, and Meta; Mohamed Elshenawy (CTO), PhD in AI from the University of Toronto, and led AI teams in different ventures; Hana Malhas (CFO), University of Michigan MBA, with deep experience in creative industries; and Abdullah Moatasem (CCO), creative director with credits at Warner Bros., Netflix, and Disney+.

Media Contact
Hana Malhas
6692369534
[email protected]
www.sinai.ai

SOURCE Sinai.ai Inc.

The ASPCA and Best Friends will work alongside LAAS leadership to implement strategic improvements designed to better serve the Los Angeles community and its animals. The initiative will focus on three core priorities:

• Preventing unnecessary shelter intake via community engagement;
• Improving in-shelter care and operational efficiency to ensure animals receive timely, coordinated care; and
• Increasing positive outcomes for animals such as adoptions, fostering and reunification with owners.

The ASPCA and Best Friends are committed to supporting LAAS over an initial three-year period, and, as part of the agreement, LAAS will commit to maintaining key positions and continuing programmatic advancements for an additional three years following the grant period, ensuring long-term impact.

“Animal sheltering nationwide has undergone a dramatic shift in recent years—from simply housing animals to prioritizing positive outcomes,” said Mayor Karen Bass. “This historic investment will enable LA Animal Services staff to place an even greater emphasis on those positive outcomes and position the department at the forefront of accountable, transparent sheltering—all with the goal of supporting pet owners and helping animals find loving homes. I’m grateful to the ASPCA and Best Friends Animal Society for these visionary grants, which will support the department’s dedicated staff, volunteers and New Hope partners as they advance humane care and help keep people and pets together.”

“If we can help LA Animal Services—one of the largest shelter systems in the country—build a future where every animal receives the care, compassion and safety they deserve,” said Matt Bershadker, ASPCA President & CEO, “we won’t just be helping transform one city, we’ll be showing communities across the country what’s possible.”

“Through collaboration, we can create permanent, systemic change in Los Angeles,” said Julie Castle, CEO, Best Friends Animal Society. “This will be a moment in history we look back on, knowing animal welfare in Los Angeles was forever changed by this groundbreaking partnership.”

“The combined support from the ASPCA and Best Friends extends beyond the immediate operations needs of LA Animal Services,” said Annette G. Ramirez, Interim General Manager for LA Animal Services. “It demonstrates a commitment to a renewed vision for animal welfare across the city to keep pets and people together, by providing support to shelter staff, and creating a faster, more efficient path for animals in our care to find loving homes.”

Through this proposed initiative, LAAS will receive $7 million in grant funding from both the ASPCA and Best Friends to support more than 20 critical staffing roles, including expanded adoption and foster teams and dedicated specialists for community cat programs. In addition, the ASPCA and Best Friends will embed four experienced staff members within LAAS facilities to provide hands-on support with training, program development and implementation, and animal health and safety.

The initiative will also introduce enhanced intake strategies, expand foster care capacity, and strengthen return-to-owner efforts, including field-based reunifications. Comprehensive training will be provided to LAAS staff, covering areas such as animal care, shelter medicine, adoption services, data management, volunteer engagement and community outreach.

As one of the largest municipal shelters in the country, LAAS serves approximately 50,000 animals and responds to more than 20,000 emergency calls involving animals and people in danger. LAAS has worked diligently to reduce overcrowding across its six shelters by offering reduced adoption fees for dogs and cats, partnering with animal-loving organizations to host special adoption weekends, and working closely with New Hope Partners, which has resulted in a placement rate of 90% or greater for dogs since 2017. The Department also provides resources for Angelenos to spay/neuter their pet and provides free pet food assistance through the weekly Pet Food Pantry, which helped more than 21,646 pets last year. Since January 2025, LAAS has continued to build upon the collaborative work surrounding fostering and pet reunification best practices, which began with the ASPCA, Best Friends and other animal welfare organizations in response to helping pets and their families affected by the Palisades fire.

This initiative marks the first time the ASPCA and Best Friends have combined resources at this scale to support a single shelter system, although both organizations have been actively supporting animal welfare efforts in the Los Angeles area for decades. Since 2014, the ASPCA has been working to assist animals in underserved communities across Los Angeles through its direct care services and programmatic investments, as well as by partnering with city, county and private agencies to provide more than $16 million in grant funding. To date, the ASPCA has spayed/neutered more than 167,000 Los Angeles pets and shelter animals at its ASPCA Spay/Neuter Clinic in South Los Angeles; provided more than 56,000 primary pet care appointments at its stationary and mobile clinics; prevented more than 14,000 kittens from entering crowded shelters through its kitten foster program; safely transported more than 70,000 dogs and cats from Los Angeles area shelters to other organizations for a better chance of adoption; and advocated for stronger animal welfare laws at the local, regional and state level.

Best Friends has been working on behalf of Los Angeles’s pets since 1992 when it started volunteer programs with LAAS. Since that time, Best Friends has invested more than $80 million to support lifesaving programs across Los Angeles—conserving local resources and improving outcomes for the most at-risk animals—by partnering with LAAS through grants and hands-on operational support. Since 2012, Best Friends has expanded spay/neuter and community services (including vaccines, microchips, and high-volume spay/neuter and TNVR surgeries at no cost); founded and continues to lead the No-Kill Los Angeles (NKLA) Coalition of 160 shelters and rescue groups to coordinate solutions with LAAS leadership; and operated key adoption and spay/neuter centers under city contracts (Northeast Valley beginning in 2012 and Jefferson Park beginning in 2018). Best Friends has directly transferred more than 55,000 animals from LAAS shelters to increase lifesaving and strengthened volunteer and foster capacity (including 1.6 million volunteer hours and fast-tracking neonatal kittens into foster during kitten season). Together, these strategies have supported LAAS in saving 36,783 cats and dogs in 2025.

Together, the ASPCA and Best Friends Animal Society are partnering with LAAS to strengthen care for animals and better support the community. By combining funding, expertise and on-the-ground support, this effort is designed to deliver immediate improvements while building a more effective and sustainable shelter system for the future.

About the ASPCA^®
The ASPCA^® (The American Society for the Prevention of Cruelty to Animals^®) believes every animal deserves to live free from suffering. For 160 years, we’ve been on the frontlines to save, transform and protect millions of lives in the fight against animal cruelty. As the nation’s first and leading animal welfare organization, we assist animals in need through on-the-ground disaster and cruelty interventions, behavioral rehabilitation, animal relocation and placement, legal and legislative advocacy, and the advancement of the sheltering and veterinary communities through research, training and resources. As a 501(c)(3) not-for-profit corporation with more than 2 million supporters nationwide, our commitment to eliminating animal cruelty is unwavering. For more information, visit aspca.org, and follow the ASPCA on Facebook, X, Instagram, LinkedIn and TikTok.

About Best Friends Animal Society^®
Best Friends Animal Society is a leading animal welfare organization dedicated to saving the lives of dogs and cats in America’s shelters and making the entire country no-kill. Founded in 1984, Best Friends runs lifesaving facilities and programs nationwide in partnership with more than 6,000 shelters and rescue organizations. From our headquarters in Kanab, Utah, we also operate the nation’s largest no-kill animal sanctuary — a destination that brings our mission to life for thousands of visitors each year. We maintain the most comprehensive animal sheltering data in the country and make it accessible to the public — empowering communities with critical insights into the needs of their local shelters and how they can help. We believe every dog and cat deserves a home. And we believe that, by working together, we can Save Them All®.

About LA Animal Services
LA Animal Services promotes and protects the health, safety, and welfare of animals and the people who love them, and is one of the largest municipal shelter systems in the United States. With six Centers across the City, LA Animal Services serves approximately 50,000 animals annually and responds to 20,000 emergency calls involving animals or people in danger. For LA Animal Services, there’s no place like home so the Department provides resources to keep pets and families together; helps lost pets get home quickly without having to enter the shelter system; provides pet food assistance; and continues to build on a strong adoption and foster program so pets find loving homes or are placed in foster care. Visit our link.tree for helpful links to the services and resources available to you and your companion animals. Connect with LA Animal Services and follow us on Facebook, Instagram, and X.

SOURCE ASPCA

STOCKHOLM, Sweden, April 20, 2026 — Between 13 April 2026 and 17 April 2026 EQT AB (LEI code 213800U7P9GOIRKCTB34) (“EQT”) has repurchased in total 318,372 own ordinary shares (ISIN: SE0012853455).

The repurchases form part of the repurchase program of a maximum of 3,005,071 own ordinary shares for a total maximum amount of SEK 2,500,000,000 that EQT announced on 4 March 2026. The repurchase program, which runs between 4 March 2026 and 8 May 2026, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052.

EQT ordinary shares have been repurchased as follows:

All acquisitions have been carried out on Nasdaq Stockholm by Skandinaviska Enskilda Banken AB on behalf of EQT.

Following the above acquisitions and as of 17 April 2026, the number of shares in EQT, including EQT’s holding of own shares is set out in the table below.

1) Total number of shares in EQT AB, i.e. including the number of shares owned by EQT AB
2) EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders’ meetings

A full breakdown of the transactions is attached to this announcement.

Contact

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/repurchases-of-shares-by-eqt-ab-during-week-16–2026,c4337261

The following files are available for download:

NEW YORK, 20. April 2026 — Pulnovo Medical, ein Pionier für bahnbrechende Therapien zur Behandlung von pulmonaler Hypertonie und Herzinsuffizienz, gab heute den erfolgreichen Abschluss einer überzeichneten strategischen Finanzierungsrunde von 100 Millionen US-Dollar bekannt, an der sich Medtronic, eines der weltweit größten Medizintechnikunternehmen, als federführender Investor mit anhaltender Unterstützung von bestehenden Investoren wie EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed und Lilly Asia Ventures beteiligte. Pulnovo begrüßt außerdem neue Investoren, darunter HSG (ehemals Sequoia China) und andere prominente globale Investoren. Diese Finanzierung stellt einen bedeutenden Meilenstein auf dem globalen Wachstumskurs von Pulnovo dar und spiegelt das starke Vertrauen führender strategischer sowie institutioneller Investoren in die Technologie des Unternehmens, seine klinischen Fortschritte sowie seine langfristige Vision wider.

Gesondert davon haben Medtronic und Pulnovo eine kommerzielle Vereinbarung geschlossen, die potenzielle zukünftige Vermarktungsmöglichkeiten vorsieht. Die Vereinbarung soll die kommerziellen Synergien zwischen Pulnovo und Medtronic sowie die besondere und umfassende globale Vermarktungskompetenz von Medtronic nutzen.

Pulnovos firmeneigenes Pulmonary Artery Denervation (PADN) System setzt an einem zentralen zugrunde liegenden Mechanismus kardiopulmonaler Erkrankungen an und hat signifikante klinische Vorteile gezeigt, darunter Verbesserungen der funktionellen Kapazität sowie der Behandlungsergebnisse der Patienten. Bis heute hat das Unternehmen weltweit etwa 1500 PADN-Verfahren durchgeführt und in sieben Ländern behördliche Zulassungen erhalten, was seine wachsende internationale Präsenz untermauert. Pulnovo treibt die Vermarktung in der Europäischen Union, im Nahen Osten und in China voran.

In den Vereinigten Staaten hat Pulnovo die Breakthrough-Device-Auszeichnung der FDA erhalten und zwei vollständig genehmigte Studien im Rahmen einer Investigational Device Exemption (IDE) eingeleitet, die beide von Dr. Gregg Stone, leitendem Hochschullehrer und Professor am Mount Sinai, geleitet werden.

„Durch die Verbindung von Branchenexpertise und langfristigem Kapital baut Pulnovo ein skalierbares Wachstumsmodell auf, das auf firmeneigener Innovation, globaler klinischer Entwicklung sowie strategischen Partnerschaften innerhalb des Ökosystems basiert. Diese Finanzierung markiert einen entscheidenden Übergang von einer produktgetriebenen Phase zu einer vollständig integrierten globalen Plattform. Während wir unsere Fähigkeiten sowohl auf klinischer als auch auf technologischer Ebene weiter stärken, bleiben wir unserem Ziel verpflichtet, Patienten weltweit bedeutsame Innovationen bereitzustellen.”

– Cynthia Chen, Vorsitzende und Präsidentin, Pulnovo Medical

EINE STRATEGISCHE PARTNERSCHAFT FÜR WELTWEITE SKALIERUNG

Diese Finanzierung stärkt Pulnovos strategische Zusammenarbeit mit globalen Industrie- und Kapitalpartnern und verbessert die Fähigkeit des Unternehmens, die klinische Entwicklung voranzutreiben, globale Zulassungsstrategien umzusetzen sowie seine kommerziellen Aktivitäten auszubauen.

Die Erlöse aus dieser Finanzierung werden zur Unterstützung der laufenden klinischen Entwicklung, für weltweite Zulassungsanträge, die internationale Vermarktung sowie weitere Investitionen in die technologische Kernplattform des Unternehmens verwendet.

Im Zuge des Ausbaus des globalen Führungsteams ist Andre Xiao als Strategieleiter dem Unternehmen beigetreten, wo er die globale Finanzierung und Strategie leiten wird. In enger Zusammenarbeit mit dem Verwaltungsrat wird Andre eine wichtige Rolle dabei spielen, Pulnovos Anbindung an die globalen Kapitalmärkte sowie Branchennetzwerke zu stärken und damit die nächste Wachstumsphase des Unternehmens zu unterstützen.

Andre verfügt über umfangreiche Erfahrung in Healthcare-Investments und auf den globalen Kapitalmärkten, darunter frühere Positionen bei führenden Investmenthäusern wie Citadel sowie Millennium Management, wo er sich auf globale Investitionen im Bereich Medizintechnik spezialisiert hat.

INFORMATIONEN ZUR PULMONALEN ARTERIENDENERVIERUNG

Pulnovos firmeneigenes Pulmonary Artery Denervation (PADN) System ist die erste minimal-invasive Therapie ihrer Klasse. Sie wurde entwickelt, um die überaktivierte Aktivität des sympathischen Nervensystems zu modulieren, die zum Umbau der pulmonalen Gefäße und zum Fortschreiten kardiopulmonaler Erkrankungen beiträgt. Da PADN auf einen zentralen Krankheitsmechanismus abzielt, hat es in globalen Studien klinisch bedeutsame Ergebnisse gezeigt, darunter Verbesserungen der funktionellen Kapazität und eine Verringerung der wichtigsten unerwünschten klinischen Ereignisse.

Die Therapie wurde in mehreren internationalen klinischen Leitlinien anerkannt, darunter durch ihre Aufnahme in die Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) und der Europäischen Atemwegsgesellschaft (ERS) aus dem Jahr 2022 zur Diagnose und Behandlung der pulmonalen Hypertonie, und wurde bislang in insgesamt sieben klinischen Leitlinien erwähnt.

Es laufen klinische Studien in verschiedenen Regionen, darunter Studien in Europa und Asien, die kurz vor dem Abschluss stehen, sowie die PULSE-LHD IDE-Studie in den Vereinigten Staaten, die vor kurzem begonnen wurde. Zusammen werden diese Studien voraussichtlich die klinische Evidenzbasis für PADN weiter stärken und das Potenzial der Therapie untermauern, einen erheblichen ungedeckten medizinischen Bedarf bei Patienten mit Herzinsuffizienz und verwandten kardiopulmonalen Erkrankungen zu decken.

Informationen zu Pulnovo Medical

Pulnovo Medical ist ein innovatives Medizintechnikunternehmen, das sich der Entwicklung interventioneller Therapien für pulmonale Hypertonie und Herzinsuffizienz widmet. Ausgerichtet auf klinischen Nutzen entwickelt das Unternehmen bahnbrechende Lösungen auf Grundlage seiner firmeneigenen Technologieplattform, mit einem Schwerpunkt auf globaler klinischer Entwicklung und Vermarktung, um die Behandlungsergebnisse von Patienten weltweit zu verbessern.

PALO ALTO, Calif., April 20, 2026 — Jonathan Tower today announced he is stepping down from Prosperity7 Ventures, the $3 billion global venture capital arm funded by Aramco, following his successful tenure as Regional Managing Director and Head of U.S. Ventures. The departure follows a period of strategic growth and strong performance of Prosperity7 in the U.S. under Tower’s leadership.

Upon joining Prosperity7 in early 2022 as its first U.S.-based executive, Tower launched and scaled the firm’s North American venture operations. During his tenure, he led the opening of Prosperity7’s Palo Alto office and New York offices, recruited a 14-person U.S. investment team, and helped establish the firm’s presence in the venture ecosystem.

Under Tower’s leadership, Prosperity7 deployed over $600 million across more than 60 companies spanning AI infrastructure, data platforms, robotics, cybersecurity, and enterprise software, including Cohere, Hammerspace, Together AI, SingleStore, Cart.com, Artera, AppOmni, Cowbell, Nile, and Jeeves.

“We built the U.S. platform from a blank slate into a fully formed venture business with a strong team and a high-conviction portfolio,” said Tower. “With AI reshaping every industry, this feels like the right moment to build again.”

Looking ahead, Tower is launching a new AI-native venture platform focused on backing founders building the next generation of AI companies and infrastructure. The new platform will combine a thesis-driven investment strategy with a media component designed to share research and insights with the broader technology and entrepreneurial community.

“Artificial Intelligence is reshaping not just the companies in which we invest – it’s changing how venture firms themselves will need to operate and compete. The venture playbook that defined the last decade won’t define the next,” Tower added. “I’m focused on building a platform that reflects that dramatic shift.”

Tower’s full reflections on his tenure and plans ahead are available on his blog at https://jtower09.medium.com/.

SOURCE Jonathan Tower

NEW YORK, 20 avril 2026 — Pulnovo Medical, pionnier des thérapies innovantes pour le traitement de l’hypertension pulmonaire et de l’insuffisance cardiaque, annonce aujourd’hui un cycle de financement stratégique sursouscrit de 100 millions de dollars, avec un investissement principal de Medtronic, l’une des plus grandes entreprises de technologie médicale au monde, ainsi que le soutien renouvelé d’investisseurs existants tels qu’EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed et Lilly Asia Ventures. Pulnovo accueille également de nouveaux investisseurs, dont HSG (anciennement Sequoia China) et d’autres investisseurs mondiaux de premier plan. Ce financement représente une étape importante dans la trajectoire de croissance de Pulnovo et reflète une forte validation d’investisseurs stratégiques et institutionnels de premier plan à l’égard de la technologie, des progrès cliniques et de la vision à long terme de la société.

Par ailleurs, Medtronic et Pulnovo ont conclu un accord commercial qui envisage de futures opportunités de mise sur le marché. L’accord est conçu pour tirer parti de la synergie commerciale entre Pulnovo et Medtronic et des capacités uniques et étendues de Medtronic en matière de mise sur le marché à l’échelle mondiale.

Solution exclusive le Pulnovo, le système PADN de dénervation de l’artère pulmonaire cible un mécanisme sous-jacent clé de la maladie cardiopulmonaire et a démontré des avantages cliniques significatifs, y compris des améliorations de la capacité fonctionnelle et des résultats pour les patients. À ce jour, la société a réalisé 1 500 procédures PADN dans le monde et a obtenu des autorisations réglementaires dans sept pays, ce qui témoigne de l’expansion de sa présence internationale. Pulnovo fait avancer la mise sur le marché dans l’Union européenne, au Moyen-Orient et en Chine.

Aux États-Unis, Pulnovo a reçu la désignation de dispositif pionnier de la FDA et a lancé deux essais IDE d’exemption des dispositifs de recherche entièrement approuvés, tous deux dirigés par le Dr Gregg Stone, Senior Faculty et professeur à Mount Sinai.

« Grâce à l’intégration de l’expertise et du capital à long terme, Pulnovo construit un modèle de croissance évolutif ancré dans l’innovation propriétaire, le développement clinique mondial et les partenariats stratégiques. Ce financement marque le passage d’une phase axée sur les produits à une plateforme mondiale entièrement intégrée. Alors que nous continuons à renforcer nos capacités tant sur le plan clinique que technologique, nous restons déterminés à apporter des innovations significatives aux patients du monde entier. »

– Cynthia Chen, présidente du conseil et présidente de Pulnovo Medical

UN PARTENARIAT STRATÉGIQUE À L’ÉCHELLE MONDIALE

Ce financement renforce la collaboration stratégique de Pulnovo avec des partenaires industriels et financiers mondiaux, améliorant ainsi la capacité de la société à soutenir le développement clinique, à mettre en œuvre des stratégies réglementaires mondiales et à étendre ses activités commerciales.

Le produit de ce financement sera utilisé pour soutenir le développement clinique en cours, les soumissions réglementaires mondiales, la mise sur le marché internationale et l’investissement continu dans la plateforme technologique de base de la société.

Dans le cadre de l’expansion du leadership mondial de Pulnovo, Andre Xiao a rejoint Pulnovo en tant que directeur de la stratégie et dirigera le financement et la stratégie au niveau mondial. En étroite collaboration avec le conseil d’administration, Andre jouera un rôle clé dans le renforcement des liens de Pulnovo avec les marchés financiers mondiaux et les écosystèmes industriels, soutenant ainsi la prochaine phase de croissance de l’entreprise.

Andre possède une vaste expérience des investissements dans le secteur de la santé et des marchés financiers mondiaux. Il a notamment travaillé dans des sociétés d’investissement de premier plan telles que Citadel et Millennium Management, où il s’est spécialisé dans les investissements medtechs.

À PROPOS DE LA DÉNERVATION DE L’ARTÈRE PULMONAIRE

Le système de dénervation de l’artère pulmonaire (PADN) exclusif de Pulnovo, est une thérapie mini-invasive pionnière conçue pour moduler l’activité nerveuse sympathique suractivée qui contribue au remodelage vasculaire pulmonaire et à la progression de la maladie cardiopulmonaire. En ciblant un mécanisme sous-jacent clé de la maladie, le PADN a démontré des résultats cliniquement significatifs dans des études mondiales, y compris des améliorations de la capacité fonctionnelle et des réductions des événements cliniques indésirables majeurs.

La thérapie a été reconnue dans de nombreuses directives cliniques internationales, notamment avec son inclusion dans les lignes directives 2022 de la Société européenne de cardiologie (ESC) / Société européenne de pneumologie (ERS) pour le diagnostic et le traitement de l’hypertension pulmonaire, et a été référencée dans un total de sept directives cliniques à ce jour.

Des études cliniques sont en cours dans plusieurs régions, y compris des essais en Europe et en Asie qui sont en voie d’achèvement, ainsi que l’essai IDE PULSE-LHD aux États-Unis, qui a récemment été lancé. L’ensemble de ces études devrait renforcer la base de preuves cliniques pour le PADN et soutenir son potentiel à répondre à des besoins importants non satisfaits chez les patients souffrant d’insuffisance cardiaque et d’affections cardiopulmonaires connexes.

À propos de Pulnovo Medical

Pulnovo Medical est une société de technologie médicale innovante qui se consacre à l’avancement de thérapies interventionnelles pour l’hypertension pulmonaire et l’insuffisance cardiaque. Motivée par la création de valeur clinique, la société met au point des solutions révolutionnaires basées sur sa plateforme technologique exclusive, en se concentrant sur le développement clinique et la mise sur le marché à l’échelle mondiale afin d’améliorer les résultats pour les patients dans le monde entier.

-Pulnovo Medical anuncia una inversión estratégica de Medtronic en una ronda de financiación de 100 millones de dólares que superó las expectativas

NUEVA YORK, 20 de abril de 2026 — Pulnovo Medical, pionera en terapias innovadoras para el tratamiento de la hipertensión pulmonar y la insuficiencia cardíaca, anunció hoy la exitosa finalización de una ronda de financiación estratégica de 100 millones de dólares, con una inversión líder de Medtronic, una de las mayores empresas de tecnología médica del mundo, y el apoyo continuo de inversores ya existentes como EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed y Lilly Asia Ventures. Pulnovo también da la bienvenida a nuevos inversores, entre ellos HSG (anteriormente Sequoia China) y otros destacados inversores globales. Esta financiación representa un hito significativo en la trayectoria de crecimiento global de Pulnovo y refleja el sólido respaldo de inversores estratégicos e institucionales líderes a la tecnología, el progreso clínico y la visión a largo plazo de la compañía.

Por otra parte, Medtronic y Pulnovo han suscrito un acuerdo comercial que contempla posibles oportunidades de comercialización futuras. El acuerdo busca aprovechar la sinergia comercial entre Pulnovo y Medtronic, así como la amplia y singular capacidad de comercialización global de Medtronic.

El sistema patentado de denervación de la arteria pulmonar (PADN) de Pulnovo actúa sobre un mecanismo subyacente clave de las enfermedades cardiopulmonares y ha demostrado beneficios clínicos significativos, incluyendo mejoras en la capacidad funcional y los resultados de los pacientes. Hasta la fecha, la compañía ha realizado aproximadamente 1.500 procedimientos de PADN a nivel mundial y ha obtenido las aprobaciones regulatorias en siete países, lo que respalda su creciente presencia internacional. Pulnovo está impulsando su comercialización en la Unión Europea, Oriente Medio y China.

En Estados Unidos, Pulnovo ha recibido la designación de Dispositivo Innovador por parte de la FDA y ha iniciado dos ensayos de Exención para Dispositivos de Investigación (IDE) totalmente aprobados, ambos dirigidos por el doctor Gregg Stone, profesor titular y catedrático del Mount Sinai.

 “Mediante la integración de la experiencia del sector y el capital a largo plazo, Pulnovo está construyendo un modelo de crecimiento escalable basado en la innovación propia, el desarrollo clínico global y las alianzas estratégicas con el ecosistema. Esta financiación marca una transición crucial de una fase centrada en el producto a una plataforma global totalmente integrada. A medida que seguimos fortaleciendo nuestras capacidades tanto en el ámbito clínico como tecnológico, mantenemos nuestro compromiso de ofrecer innovaciones significativas a pacientes de todo el mundo“.

— Cynthia Chen, presidenta y directora general de Pulnovo Medical

UNA ALIANZA ESTRATÉGICA DISEÑADA PARA ALCANZAR LA ESCALA GLOBAL

Esta financiación refuerza la colaboración estratégica de Pulnovo con socios globales de la industria y el capital, mejorando la capacidad de la empresa para avanzar en el desarrollo clínico, ejecutar estrategias regulatorias globales y expandir las operaciones comerciales.

Los fondos obtenidos con esta financiación se utilizarán para respaldar el desarrollo clínico en curso, las presentaciones regulatorias globales, la comercialización internacional y la inversión continua en la plataforma tecnológica principal de la empresa.

Como parte de la expansión del liderazgo global de Pulnovo, Andre Xiao se ha incorporado a la compañía como director de Estrategia, donde liderará la financiación y la estrategia a nivel mundial. Trabajando en estrecha colaboración con el Consejo de Administración, Andre desempeñará un papel fundamental en el fortalecimiento de la conexión de Pulnovo con los mercados de capitales globales y los ecosistemas del sector, impulsando así la siguiente fase de crecimiento de la empresa.

Andre aporta una dilatada experiencia en inversiones en el sector sanitario y en los mercados de capitales globales, incluyendo puestos anteriores en firmas de inversión de primer nivel como Citadel y Millennium Management, donde se especializó en inversiones globales en tecnología médica.

SOBRE LA DENERVACIÓN DE LA ARTERIA PULMONAR

El sistema patentado de denervación de la arteria pulmonar (PADN) de Pulnovo es una terapia mínimamente invasiva, pionera en su clase, diseñada para modular la hiperactivación del sistema nervioso simpático, que contribuye a la remodelación vascular pulmonar y a la progresión de la enfermedad cardiopulmonar. Al actuar sobre un mecanismo subyacente clave de la enfermedad, PADN ha demostrado resultados clínicamente significativos en estudios globales, incluyendo mejoras en la capacidad funcional y reducciones en los principales eventos clínicos adversos.

Esta terapia ha sido reconocida en múltiples guías clínicas internacionales, incluida su inclusión en las Guías de la Sociedad Europea de Cardiología (ESC) / Sociedad Respiratoria Europea (ERS) de 2022 para el diagnóstico y tratamiento de la hipertensión pulmonar, y ha sido referenciada en un total de siete guías clínicas hasta la fecha.

Actualmente se están realizando estudios clínicos en diversas regiones, incluyendo ensayos en Europa y Asia que están próximos a finalizar, así como el ensayo PULSE-LHD IDE en Estados Unidos, que se ha iniciado recientemente. Se espera que, en conjunto, estos estudios refuercen la evidencia clínica sobre PADN y avalen su potencial para abordar necesidades médicas importantes no cubiertas en pacientes con insuficiencia cardíaca y afecciones cardiopulmonares relacionadas.

Acerca de Pulnovo Medical

Pulnovo Medical es una empresa innovadora de tecnología médica dedicada al avance de las terapias intervencionistas para la hipertensión pulmonar y la insuficiencia cardíaca. Impulsada por el valor clínico, la empresa desarrolla soluciones revolucionarias basadas en su plataforma tecnológica propia, con un enfoque en el desarrollo clínico global y la comercialización para mejorar los resultados de los pacientes en todo el mundo.

SHANGHAI, April 20, 2026 — Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per share and opened at $22.6 per share with a market capitalization of approximately $1.5 billion.

Qiming Venture Partners led Alamar’s Series A financing in 2020 and continued to fund the company’s development in the following Series B and Series C rounds. Before the company’s IPO, Qiming Venture Partners held approximately 19.2% stake in Alamar and was one of its most important institutional investors.

Founded in 2018, Alamar is a commercial-stage proteomics company dedicated to developing and commercializing proteomics technologies and establishing the gold standard in protein detection and analysis. Alamar’s self-developed NULISA™ technology breaks through the design limitations of existing proteomics tools, delivering ultra-high sensitivity, high specificity, flexible multiplex protein detection, broad dynamic range and seamless automation to detect protein biomarkers at extremely low concentrations, filling a critical gap previously uncovered by other protein detection methods.

In addition, the company’s self-developed ARGO™ HT fully automated, high-throughput system enables a “sample-to-answer” automated workflow, driving rapid growth in product market penetration. As of the end of 2025, the ARGO™ HT system had accumulated an installed base of over 100 instruments, serving more than 300 customers across 25 countries. Since the commercialization of its platform, the number of scientific articles published based on its technologies and products has exceeded 100.

“Congratulations to Alamar on its successful listing. We firmly believe that ultra-high-sensitivity proteomics will innovatively transform the future of early disease screening and precision diagnostics.” said William Hu, Managing Partner of Qiming Venture Partners. “Guided by this original investment vision, we are delighted to have backed Alamar at an early stage and supported the company throughout its growth journey. We look forward to Alamar building on its world-leading proteomics platform to deliver earlier, more accurate and more accessible precision diagnostics, drive cutting-edge healthcare technologies into clinical practice to benefit the public, and create long-term value for global patients and the healthcare system.”

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

SOURCE Qiming Venture Partners